Endothelial Function and Endothelial Progenitor Cells in Systemic Lupus Erythematosus

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2022 Apr 8

PMID 35393604

Authors

Anselm Mak

Jerry Kok Yen Chan

Affiliations

Soon will be listed here.

Abstract

The observations that traditional cardiovascular disease (CVD) risk factors fail to fully account for the excessive cardiovascular mortality in patients with systemic lupus erythematosus (SLE) compared with the general population have prompted in-depth investigations of non-traditional, SLE-related risk factors that contribute to cardiovascular complications in patients with SLE. Of the various perturbations of vascular physiology, endothelial dysfunction, which is believed to occur in the earliest step of atherosclerosis, has been extensively investigated for its contribution to CVD risk in SLE. Endothelial progenitor cells (EPCs), which play a crucial part in vascular repair, neovascularization and maintenance of endothelial function, are quantitatively and functionally reduced in patients with SLE. Yet, the lack of a unified definition of EPCs, standardization of the quantity and functional assessment of EPCs as well as endothelial function measurement pose challenges to the translation of endothelial function measurements and EPC levels into prognostic markers for CVD in patients with SLE. This Review discusses factors that contribute to CVD in SLE, with particular focus on how endothelial function and EPCs are evaluated currently, and how EPCs are quantitatively and functionally altered in patients with SLE. Potential strategies for the use of endothelial function measurements and EPC quantification as prognostic markers of CVD in patients with SLE, and the limitations of their prognostication potential, are also discussed.

Citing Articles

The Role of Immune Cells in Moyamoya Disease.

Wang S, Jiang Q, Liu Y, Zhang X, Huang Y, Zhang H Brain Sci. 2025; 15(2).

PMID: 40002470 PMC: 11852451. DOI: 10.3390/brainsci15020137.

Exploring novel markers for coronary heart disease associated with systemic lupus erythematosus: A review.

Du L, Wang Y, Ma H, Fan J, Wang S, Liu J Medicine (Baltimore). 2024; 103(50):e40773.

PMID: 39686502 PMC: 11651451. DOI: 10.1097/MD.0000000000040773.

Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus.

Rafael-Vidal C, Martinez-Ramos S, Malvar-Fernandez B, Altabas-Gonzalez I, Mourino C, Pazos-Lopez P Arthritis Res Ther. 2024; 26(1):170.

PMID: 39342288 PMC: 11438060. DOI: 10.1186/s13075-024-03397-4.

Predicting the risk of cardiovascular and cerebrovascular event in systemic lupus erythematosus: a Chinese SLE treatment and research group study XXVI.

Huang C, Li Y, Wang Z, Lin S, Zhao J, Wang Q RMD Open. 2024; 10(3).

PMID: 39313305 PMC: 11418496. DOI: 10.1136/rmdopen-2024-004425.

Positron emission tomography probes for stem cell monitoring: a review.

Xu L, Shi J, Wu S Am J Transl Res. 2024; 16(8):3534-3544.

PMID: 39262689 PMC: 11384350. DOI: 10.62347/CIUT6327.

References

Jonsson H, Nived O, Sturfelt G . Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore). 1989; 68(3):141-50. View

Manzi S, Meilahn E, Rairie J, Conte C, Medsger Jr T, DAgostino R . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145(5):408-15. DOI: 10.1093/oxfordjournals.aje.a009122. View

Bernatsky S, Boivin J, Joseph L, Manzi S, Ginzler E, Gladman D . Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54(8):2550-7. DOI: 10.1002/art.21955. View

Goldberg R, Urowitz M, Ibanez D, Nikpour M, Gladman D . Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol. 2009; 36(11):2454-61. DOI: 10.3899/jrheum.090011. View

Colombo B, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G . Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2008; 8(4):309-15. DOI: 10.1016/j.autrev.2008.10.002. View

Moghaddam B, Marozoff S, Li L, Sayre E, Zubieta J . All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study. Rheumatology (Oxford). 2021; 61(1):367-376. PMC: 8742828. DOI: 10.1093/rheumatology/keab362. View

Leonard D, Svenungsson E, Sandling J, Berggren O, Jonsen A, Bengtsson C . Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet. 2013; 6(3):255-63. DOI: 10.1161/CIRCGENETICS.113.000044. View

Bahrehmand F, Vaisi-Raygani A, Kiani A, Rahimi Z, Tavilani H, Navabi S . Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus. 2012; 21(6):616-24. DOI: 10.1177/0961203312436857. View

Bicakcigil M, Tasan D, Tasdelen N, Mutlu N, Yavuz S . Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients. Lupus. 2011; 20(10):1063-71. DOI: 10.1177/0961203311404911. View

10.

Troelsen L, Garred P, Christiansen B, Torp-Pedersen C, Jacobsen S . Genetically determined serum levels of mannose-binding lectin correlate negatively with common carotid intima-media thickness in systemic lupus erythematosus. J Rheumatol. 2010; 37(9):1815-21. DOI: 10.3899/jrheum.100158. View

11.

Marasini B, Massarotti M, De Monti M, Erario M, Ghilardi G, Biondi M . Genetic contribution to carotid vascular disease in patients with systemic lupus erythematosus. J Clin Immunol. 2007; 28(2):131-3. DOI: 10.1007/s10875-007-9146-3. View

12.

Szalai A, Alarcon G, Calvo-Alen J, Toloza S, McCrory M, Edberg J . Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford). 2005; 44(7):864-8. DOI: 10.1093/rheumatology/keh613. View

13.

Frieri M . Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep. 2011; 12(1):25-32. DOI: 10.1007/s11882-011-0236-1. View

14.

Medeiros P, Salomao R, Teixeira S, Rassi D, Rodrigues L, Aragon D . Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus. Pediatr Rheumatol Online J. 2021; 19(1):35. PMC: 7981852. DOI: 10.1186/s12969-021-00513-5. View

15.

Faurschou M, Mellemkjaer L, Starklint H, Kamper A, Tarp U, Voss A . High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol. 2011; 38(11):2400-5. DOI: 10.3899/jrheum.110329. View

16.

Ajeganova S, Hafstrom I, Frostegard J . Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid.... Lupus Sci Med. 2021; 8(1). PMC: 7871345. DOI: 10.1136/lupus-2020-000454. View

17.

Montarello N, Nguyen M, Wong D, Nicholls S, Psaltis P . Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. Cardiovasc Drugs Ther. 2020; 36(2):347-362. DOI: 10.1007/s10557-020-07106-6. View

18.

Oikonomou E, Leopoulou M, Theofilis P, Antonopoulos A, Siasos G, Latsios G . A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. Atherosclerosis. 2020; 309:16-26. DOI: 10.1016/j.atherosclerosis.2020.07.027. View

19.

Miller A, McInnes I . Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des. 2011; 17(1):1-8. DOI: 10.2174/138161211795049796. View

20.

Steyers 3rd C, Miller Jr F . Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014; 15(7):11324-49. PMC: 4139785. DOI: 10.3390/ijms150711324. View